explore -WSS

explore

author：fashion 2025-09-14 21:55:03 - browse：2944

The Dr. Gary B. and Pamela S. Williams Tower in Summa Health System's Akron Campus — Summa Health

General Catalysts’s grand vision for a venture capital-owned hospital system seamlessly blending AI and tech into everyday appointments and rewarding staff for keeping patients healthy might sound alluring. But the firm’s bold experiment is facing hurdles even before it has started as the community served by the health system it hopes to buy is pushing back.

The Health Assurance Transformation Corp., a General Catalyst entity known as HATCo, unveiled plans last month to acquire Akron safety net provider Summa Health. But since the announcement, residents and local officials have raised questions about who the deal benefits, and who gets left behind.

On Thursday, the Mayor of Akron plans to press HATCo’s chief executive, Marc Harrison, who previously led Intermountain Health, on whether his plan is a profit play or a longer-term investment in the community. At the forefront are citizens’ concerns that the deal will drive up costs, eliminate jobs, reduce the quality of care or even shutter one of just two major hospital systems in the area, about a fifth of whose patients are on Medicaid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

hotspot

WSS

Fauci’s Covid grilling leads GOP to weigh foreign research rules

How generative AI ratchets up security threats for health systems

Idaho abortion case may prompt more restrictions in other states

As JPM 2024 winds down, some health tech firms project optimism

Investment in vaccine development is lagging, report finds

How I ended up pumping milk in a bathroom stall at JPM 2024

explore

explore

focus

Medicare proposal to cover medical devices draws a mixed reaction

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Jerome Adams on the need for new antivirals for Covid

The SUPPORT Act is critical to fighting the opioid crisis

The cancer drug shortage isn’t new — and neither are the solutions

Reconstructing family trees of blood cells may help predict disease

Medicare proposal to cover medical devices draws a mixed reaction

Humana’s losses in Medicare Advantage tank its stock

Trump demands the U.S. pay no more for drugs than other countries … again

Why Medicare shouldn’t cover every FDA

entertainment

Readout LOUD podcast: live from JPM 2024

Pancreatic cancer early detection could be helped by AI

Vertex non

Caregivers of transplant patients call for more support, training

Philips to halt sales of sleep apnea machines in U.S.

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

explore

leisure time

hotspot

focus